Please amend this application as follows:

Amendments to the Claims

1-12. (cancelled)

13. (currently amended) A method of treating myocardial infarction, comprising administering an effective amount of a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives to a patient in need thereof.

14. (previously presented) The method of claim 13, wherein the compound is administered at a dose between 0.25 and 6 pmol/kg/min.

15. (previously presented) The method of claim 14, wherein the dose is between 0.5 to about 2.4 pmol/kg/min.

16. (previously presented) The method of claim 15, wherein the dose is between 0.5 to about 1.2 pmol/kg/min.

17-20. (cancelled)

21. (new) A method of reducing mortality and morbidity after myocardial infarction, comprising administering to a patient who is incapable of autoregulation of blood glucose, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof, at a dose effective to normalize blood glucose and by an administration method that maintains normal glucose levels.

22. (new) A method of reducing mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, a buffer, and a preservative at a dose effective to normalize blood glucose.